Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old): Evaluating the Efficacy of a Nelarabine Based Consolidation and Maintenance in High-risk Patients

Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old): Evaluating the Efficacy of a Nelarabine Based Consolidation and Maintenance in High-risk Patients

Essai thérapeutique randomisé de phase III évaluant la diminution des doses de chimiothérapie en association avec du nilotinib (Tasigna ®) dans les LAL à chromosome de Philadelphie positive (Ph+) de l’adulte jeune (18-59 ans).

Etude internationale pour le traitement des rechutes de leucémies aiguës lymphoblastiques de l’enfant à haut risque

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia